Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) closed the day trading at $11.08 down -0.27% from the previous closing price of $11.11. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 1204626 shares were traded. ARQT stock price reached its highest trading level at $11.28 during the session, while it also had its lowest trading level at $10.74.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
For a better understanding of ARQT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.40 and its Current Ratio is at 11.60. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.94.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on September 07, 2022, initiated with a Buy rating and assigned the stock a target price of $46.
On March 17, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $45.
On June 30, 2021, Mizuho started tracking the stock assigning a Buy rating and target price of $58.Mizuho initiated its Buy rating on June 30, 2021, with a $58 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 when Watanabe Todd Franklin sold 2,435 shares for $15.26 per share. The transaction valued at 37,167 led to the insider holds 366,657 shares of the business.
Burnett Patrick sold 851 shares of ARQT for $12,989 on Mar 06. The insider now owns 59,962 shares after completing the transaction at $15.26 per share. On Mar 06, another insider, Lock Kenneth A., who serves as the Chief Commercial Officer of the company, sold 831 shares for $15.26 each. As a result, the insider received 12,684 and left with 63,429 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 192.61 while its Price-to-Book (P/B) ratio in mrq is 3.23.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $27.40, while it has fallen to a 52-week low of $10.65. The 50-Day Moving Average of the stock is 15.33, while the 200-Day Moving Average is calculated to be 19.01.
Shares Statistics:
Over the past 3-months, ARQT traded about 924.41K shares per day on average, while over the past 10 days, ARQT traded about 1.41M shares per day. A total of 61.04M shares are outstanding, with a floating share count of 58.97M. Insiders hold about 1.40% of the company’s shares, while institutions hold 98.40% stake in the company. Shares short for ARQT as of Jan 30, 2023 were 10.79M with a Short Ratio of 12.38M, compared to 10.65M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 17.70% and a Short% of Float of 28.19%.
Earnings Estimates
Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of -$1.36 and a low estimate of -$1.71, while EPS last year was -$1.42. The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.3 and low estimates of -$1.43.
Analysts are recommending an EPS of between -$5.85 and -$6.25 for the fiscal current year, implying an average EPS of -$5.93. EPS for the following year is -$4.62, with 9 analysts recommending between -$3.47 and -$5.28.
Revenue Estimates
Based on 9 analysts’ estimates, the company’s revenue will be $50.51M in the next fiscal year. The high estimate is $80.6M and the low estimate is $20.7M. The average revenue growth estimate for next year is up 1,697.50% from the average revenue estimate for this year.
